TRCT
TMDX icon

Tower Research Capital (TRC)’s Transmedics TMDX Stock Holding History

Tower Research Capital (TRC)’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$294K Buy
4,422
+2,030
+85% +$172K 0.01% 1403
2026
Q1 		$238K Sell
2,392
-1,360
-36% -$177K 0.01% 1486
2025
Q4 		$456K Buy
3,752
+2,215
+144% +$278K 0.01% 878
2025
Q3 		$172K Sell
1,537
-2,053
-57% -$240K ﹤0.01% 1582
2025
Q2 		$481K Buy
3,590
+3,165
+745% +$348K 0.01% 1018
2025
Q1 		$28.6K Sell
425
-3,934
-90% -$271K ﹤0.01% 2658
2024
Q4 		$272K Buy
4,359
+4,103
+1,603% +$382K 0.01% 1491
2024
Q3 		$40.2K Sell
256
-4,692
-95% -$723K ﹤0.01% 2844
2024
Q2 		$745K Buy
4,948
+4,501
+1,007% +$540K 0.01% 1001
2024
Q1 		$33.1K Sell
447
-6,136
-93% -$506K ﹤0.01% 2576
2023
Q4 		$520K Buy
6,583
+3,105
+89% +$187K 0.01% 1338
2023
Q3 		$190K Buy
3,478
+2,596
+294% +$187K 0.01% 1459
2023
Q2 		$74.1K Buy
882
+289
+49% +$22.1K ﹤0.01% 2266
2023
Q1 		$45K Sell
593
-3,995
-87% -$276K ﹤0.01% 2597
2022
Q4 		$283K Buy
4,588
+1,985
+76% +$106K 0.01% 1064
2022
Q3 		$109K Buy
2,603
+1,448
+125% +$63K ﹤0.01% 2492
2022
Q2 		$36K Buy
1,155
+816
+241% +$21.8K ﹤0.01% 3196
2022
Q1 		$9K Sell
339
-1,843
-84% -$33K ﹤0.01% 4497
2021
Q4 		$41K Buy
2,182
+1,776
+437% +$44.5K ﹤0.01% 2926
2021
Q3 		$13K Sell
406
-3,226
-89% -$98.6K ﹤0.01% 4102
2021
Q2 		$121K Sell
3,632
-1,313
-27% -$36.4K ﹤0.01% 2279
2021
Q1 		$206K Buy
4,945
+2,697
+120% +$83K ﹤0.01% 1986
2020
Q4 		$45K Sell
2,248
-18,987
-89% -$281K ﹤0.01% 3221
2020
Q3 		$293K Buy
21,235
+17,339
+445% +$297K ﹤0.01% 2210
2020
Q2 		$70K Buy
3,896
+514
+15% +$8.04K ﹤0.01% 2779
2020
Q1 		$41K Buy
3,382
+2,804
+485% +$47K ﹤0.01% 1385
2019
Q4 		$11K Sell
578
-3,224
-85% -$59.2K ﹤0.01% 2296
2019
Q3 		$90K Sell
3,802
-2,749
-42% -$65.9K 0.01% 1421
2019
Q2 		$190K Buy
+6,551
New +$179K 0.01% 874

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Tower Research Capital (TRC)'s TMDX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Transmedics (TMDX) stake by 85% in Q2 2026, buying an estimated $172K and bringing the position to 4,422 shares worth $294K. The position accounts for 0.01% of the portfolio, ranked #1403.

Tower Research Capital (TRC) first reported a position in TMDX in Q2 2019 and has held it in 29 quarters since. The position peaked at $745K in Q2 2024. 374 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

  • Tower Research Capital (TRC) held 4,422 shares of Transmedics worth $294K as of Q2 2026.
  • Tower Research Capital (TRC) bought 2,030 Transmedics shares in Q2 2026, an estimated $172K.
  • Transmedics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #1403 holding.
  • Tower Research Capital (TRC) first reported a position in Transmedics in Q2 2019 and has held it in 29 quarters since.
  • Tower Research Capital (TRC)'s Transmedics position peaked at $745K in Q2 2024.
  • 374 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.